who should not take GLP-1 long term — Valley Bariatric Mesa AZ

The Formal Contraindications — and Why They Exist

The FDA-labeled contraindications for GLP-1 receptor agonists like semaglutide and tirzepatide are not arbitrary. They reflect specific, known risks. Patients deserve to understand what those risks actually are — not just that a box was checked on a form.

The most prominent is the boxed warning for personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. This warning comes from rodent studies that showed C-cell changes and medullary thyroid tumors after GLP-1 receptor stimulation.

Here is the important nuance: rodent thyroid C-cells express GLP-1 receptors in a way that human C-cells do not. That is why more than a decade of post-marketing data has not produced a convincing human signal. A 2026 white paper from the nation's largest thyroid cancer center reached the same conclusion — no convincing evidence of increased medullary thyroid cancer risk in humans.

Even so, the contraindication stands. For patients with MTC in their family history, we do not prescribe GLP-1 medications. The theoretical risk, even unproven, is not one we take on when alternatives exist.

Pancreatitis history is different. It is not an absolute contraindication but a labeled warning. GLP-1 medications slow gastric emptying and change pancreatic signaling. This has been linked to post-marketing cases of acute pancreatitis, including severe forms.

Meta-analyses have not established a clear causal link. A 2025 analysis published in the Journal of Clinical Medicine found no statistically meaningful increase in pancreatitis risk in a comorbidity-free type 2 diabetes group. But patients with a documented history of pancreatitis were excluded from the major clinical trials. We have no safety data for that group.

In our practice, a history of pancreatitis — especially recurrent or severe episodes — means GLP-1 is off the table.

Severe gastroparesis is a contraindication because it is also the mechanism. GLP-1 medications slow gastric emptying by up to 50% at peak effect. That is a key part of how they reduce appetite. For a patient whose stomach already empties slowly, adding a medication that slows it further creates real clinical risk — nausea, vomiting, aspiration risk, and worsening of the underlying motility problem.

There has been active post-marketing litigation around gastroparesis cases. Causation in individual cases is often hard to establish. But the mechanism is clear enough that we treat this as a genuine contraindication.

Patients Without Contraindications Who Are Still on the Wrong Long-Term Plan

This is where the clinical picture gets more complicated. These are patients who passed initial screening. No personal history of thyroid cancer, no prior pancreatitis, no documented gastroparesis. They're on GLP-1 — often prescribed elsewhere, often without any ongoing clinical oversight.

For some of them, long-term GLP-1 use is still not the right plan.

Patients with a history of eating disorders — especially binge eating disorder — need careful evaluation before starting GLP-1. They also need close monitoring if they are already on it. The appetite suppression that makes GLP-1 effective in most patients can mask — rather than treat — the behavioral and psychological patterns that drive disordered eating.

We have seen patients who appear to be doing well on GLP-1 by the numbers. But they are not eating structured meals. They are not engaging with behavioral support. Their relationship with food has not changed — it has just been suppressed by medication. When GLP-1 stops, for any reason, those patients are in a harder position than before. The ADA flags this group specifically and recommends careful psychiatric screening. That screening is not consistently happening in high-volume prescribing settings.

Muscle mass is a real concern that does not get enough attention at the prescribing stage. GLP-1 medications reduce appetite without distinguishing between fat mass and lean mass. In practice, a meaningful share of weight lost on GLP-1 — estimates across multiple trials range from 20% to 40% of total weight — comes from lean tissue, not fat.

For a younger, active patient with strong baseline lean mass, that is manageable with deliberate protein intake and resistance training. For an older patient, or one with already-low lean mass, that muscle loss is not trivial. There is a developing signal in post-marketing data around bone mineral density decline and fracture risk with long-term use. We monitor our GLP-1 patients for this specifically.

That does not mean GLP-1 is wrong for older patients across the board. It means it requires active management of protein, strength training, and lab monitoring. That is not happening when GLP-1 is prescribed at arm's length.

Access is a clinical variable, not just a financial one. GLP-1 medications cost roughly $12,000 or more per year at list price. Nearly half of patients who start them stop within the first year — often because of cost. Insurance coverage is inconsistent and can change.

A patient who loses 18% of their body weight on semaglutide and then stops it without a surgical alternative in place will, in most cases, regain a significant portion of that weight. We are honest with patients about this. If your access to this medication is uncertain — if your coverage could lapse, if the out-of-pocket cost is not sustainable — then building your entire long-term plan around it carries real risk. That is not a judgment. It is a clinical reality about treatment durability that should be part of any informed consent conversation.

When the Clinical Picture Points to Surgery

There is a patient profile we see regularly in our practice. BMI above 40, two or three significant metabolic health conditions, a history of multiple failed non-surgical treatments, and now a year or more on GLP-1 with results that have plateaued or never met the clinical threshold needed to reduce disease burden.

This patient does not have a GLP-1 contraindication. They are tolerating the medication. But GLP-1 alone is not going to be enough for them. The longer they stay on it without a clear escalation plan, the longer they delay a more effective treatment.

The ASMBS has been clear that GLP-1 medications are tools that work alongside surgery — not replacements for surgery in patients for whom surgery is indicated. The Endocrine Society and ADA position is consistent. Bariatric surgery remains the most effective long-term treatment for patients with BMI 40 or above, or BMI 35 and above with significant health conditions, who have not achieved enough response from medication treatment. GLP-1 is medication treatment. When it does not produce a sufficient response, the next step is surgery — not a higher dose, not a different GLP-1, not more waiting.

We also recognize that some patients come to us specifically asking whether they can switch from GLP-1 to surgery after trying medication first. That transition is well-supported by the literature. It is a reasonable path. What we counsel against is staying on a medication indefinitely — with no defined endpoint — when the clinical picture suggests it is unlikely to be enough. That is not a plan. It is a delay.

The GI Motility Gray Zone

Severe gastroparesis is a formal contraindication. But there is a less-discussed group: patients with significant GI issues that fall short of that threshold. These patients have real underlying motility problems — slow bowel, chronic constipation, prior GI surgeries, or inflammatory bowel disease affecting the upper GI tract.

For these patients, the gastric emptying effects of GLP-1 create a real burden. Nausea, reflux, bloating, and constipation can be severe enough to affect quality of life, medication use, and nutritional intake.

We see patients who have been on GLP-1 for months, eating very little because food makes them feel terrible. They are losing muscle mass because their protein intake has collapsed. They are losing weight, technically. But what they are losing is not what we are trying to target.

This is not always a reason to stop GLP-1. Sometimes dose adjustment, timing changes, and dietary modifications help substantially. But it is a reason for close clinical monitoring. This patient needs a physician — not just a prescription.

What We Tell Patients in Consultation

When a patient comes to us who has been on GLP-1 from a telehealth provider or a med spa with no lab monitoring, no body composition assessment, and no plan for what happens if the medication stops — the first thing we tell them is that they have been getting a prescription, not a treatment plan.

The Momentum program at Valley Bariatric exists because properly managed GLP-1 treatment looks different from high-volume GLP-1 prescribing. We check labs. We monitor lean mass. We have a real conversation about eating disorder history before anyone starts the medication. We track what happens to bone density over time.

And we are direct with patients when the clinical picture suggests GLP-1 is not going to get them where they need to go. We can offer the alternative. Being honest about that is what actually serves the patient.

When patients ask about the thyroid cancer risk, we explain exactly what the evidence shows. There is a rodent signal. There is no convincing human signal. The contraindication for MTC and MEN2 families is maintained as a precaution. We do not dismiss the concern, but we do not amplify it either. For patients who were never told about that warning by their previous prescriber, this conversation is part of what informed consent should have looked like from the beginning.

What we want for every patient is a plan that has a realistic chance of working long-term. Not just in month three when the medication is at full effect — but in year three, when access may have changed, when life may have changed, and when the body may have adapted. For some patients, GLP-1 within a supervised program is exactly the right plan. For others, surgery is the clearer path.

We tell patients which one we think applies to them, and we explain why. If you want to understand how GLP-1 and surgery compare on long-term failure rates, that is worth reviewing before your consultation.